Use of elicited iridaceae plant cells in the treatment of sensitive skin

Patent metadata

Field	Value
Publication number	US-10786539-B2
Application number	US-201414764231-A
Country	US
Kind code	B2
Filing date	Jan 29, 2014
Priority date	Jan 29, 2013
Publication date	Sep 29, 2020
Grant date	Sep 29, 2020

Abstract

This invention relates to the use of Lactobacillus delbrueckii to elicit a plant cell of an Iridaceae and the use of these elicited cells in treating sensitive skins.

First claim

The invention claimed is:

1. A composition having a CGRP antagonist activity of at least about 70% that is obtained by a method of preparation comprising the steps:
a) placing in contact, in a culture medium, plant cells from the Iris genus with Lactobacillus delbrueckii under conditions suitable for inducing the expression of a CGRP antagonist activity,
b) optionally separating plant cells cultivated in step a) from the culture medium, and
c) recovering a composition with CGRP antagonist activity of at least about 70%.

2. The composition according to claim 1 wherein the CGRP antagonist activity is about 100%.

3. A cosmetic or pharmaceutical composition comprising a composition having a CGRP antagonist activity of at least about 70% according to claim 1 , and a cosmetically acceptable carrier or a pharmaceutically acceptable carrier, wherein the amount of the composition having a CGRP antagonist activity is from 0.001% to 20% by weight based upon the total weight of the cosmetic or pharmaceutical composition.

4. The cosmetic or pharmaceutical composition according to claim 3 wherein the CGRP antagonist activity is about 100%.

5. The cosmetic or pharmaceutical composition according to claim 3 , being in the form of an emulsion and containing from 0.3% to 30% by weight of at least one emulsifier based upon the total weight of the cosmetic or pharmaceutical composition.

6. The cosmetic or pharmaceutical composition according to claim 3 , being a cosmetic composition containing at least one additive selected from the group of hydrophilic or lipophilic gelling agents, preservatives, antioxidants, solvents, perfumes, bulking agents, filters, odor absorbers and dyes.

7. The cosmetic composition according to claim 6 , wherein the amount of said at least one additive is from 0.01 to 10% by weight of the total weight of the cosmetic composition.

8. A composition having a CGRP antagonist activity of at least about 70% that is obtained by a method of preparation comprising the steps:
a) placing in contact, in a culture medium, dedifferentiated plant cells from the Iris genus with Lactobacillus delbrueckii under conditions suitable for inducing the expression of a CGRP antagonist activity,
b) optionally separating plant cells cultivated in step a) from the culture medium, and
c) recovering a composition with CGRP antagonist activity of at least about 70%.

9. The composition according to claim 8 wherein the CGRP antagonist activity is about 100%.

10. A composition having a CGRP antagonist activity of at least about 70% that is obtained by a method of preparation comprising the steps:
a) placing in contact, in a culture medium, plant cells from Iris pallida with Lactobacillus delbrueckii under conditions suitable for inducing the expression of a CGRP antagonist activity,
b) optionally separating plant cells cultivated in step a) from the culture medium, and
c) recovering a composition with CGRP antagonist activity of at least about 70%.

11. The composition according to claim 10 wherein the CGRP antagonist activity is about 100%.

12. A cosmetic or pharmaceutical composition comprising a composition having a CGRP antagonist activity according to claim 10 , and a cosmetically acceptable carrier or a pharmaceutically acceptable carrier, wherein the amount of the composition having a CGRP antagonist activity is from 0.001% to 20% by weight based upon the total weight of the cosmetic or pharmaceutical composition.

13. The composition according to claim 12 wherein the CGRP antagonist activity is about 100%.

14. A method for preparing a composition having a CGRP antagonist activity of at least about 70% comprising the steps:
a) placing in contact, in a culture medium, plant cells of an Iridaceae with Lactobacillus delbrueckii under conditions suitable for inducing the expression of a CGRP antagonist activity,
b) optionally separating plant cells cultivated in step a) from the culture medium, and
c) recovering a composition with CGRP antagonist activity of at least about 70%.

15. A method for treating disorders associated with an excessive synthesis and/or release of CGRP, which comprises administering the composition having a CGRP antagonist activity according to claim 1 to a subject in need of the treatment of disorders associated with an excessive synthesis and/or release of CGRP.

16. The method according to claim 15 , wherein said disorder associated with an excessive synthesis and/or release of CGRP is selected from the group consisting of eczema, prurigo and Rosacea.

17. A method for treating sensitive skin which comprises applying the cosmetic composition according to claim 3 to the sensitive skin.

18. A method for treating dandruff which comprises applying the cosmetic composition according to claim 3 to hair in need of an anti-dandruff treatment.

Assignees

• Oreal

Inventors

• Martin Richard
• Hilaire Pascal

Classifications

• A61Q19/005 Primary

  Preparations for sensitive skin · CPC title

• A61K36/88 Primary

  Liliopsida (monocotyledons) · CPC title

• A61K8/99

  from microorganisms other than algae or fungi, e.g. protozoa or bacteria · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title

• A61K8/9794

  Liliopsida [monocotyledons] · CPC title